๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Marginal Zone Lymphoma(MZL)
Clinical trial register · China

Marginal Zone Lymphoma(MZL) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 3 Hangzhou 2 Nanjing 2 Guangzhou 1 Suzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing3 Hangzhou2 Nanjing2 Guangzhou1 Suzhou1
All 15 locations
Target enrolment
to

Marginal Zone Lymphoma(MZL) trials in China

10 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
NCT07654465Marginal Zone Lymphoma(MZL)
Sun Yat-sen University
Phase 2
144
Guangzhou
2026-07
Recruiting
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
NCT07355699Marginal Zone Lymphoma(MZL)
Beijing Tongren Hospital
Phase 4
88
Beijing
2025-11-25
Recruiting
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naรฏve MZL.
NCT07372365Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital of Soochow University
Phase 2
23
Suzhou
2025-10-24
Active, closed
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
NCT07480863Marginal Zone Lymphoma(MZL)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
65
Beijing
2025-10-01
Active, closed
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
NCT07247383Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
39
Hangzhou
2025-09-19
Recruiting
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
NCT07208981Marginal Zone Lymphoma(MZL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
169
Nanjing
2025-08-14
Recruiting
Orelabrutinib Combined With Rituximab ยฑ Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
NCT07448324Marginal Zone Lymphoma(MZL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
50
Nanjing
2025-04-01
Recruiting
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT07022223Marginal Zone Lymphoma(MZL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
NCT06793189Marginal Zone Lymphoma(MZL)
Ruijin Hospital
Phase 2
145
Shanghai, Shenyang, Beijing
2025-01-23
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/marginal-zone-lymphoma-mzl

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Marginal Zone Lymphoma(MZL).

How many Marginal Zone Lymphoma(MZL) trials are recruiting in China?

7 of the 10 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Marginal Zone Lymphoma(MZL)), 10 studies
PhaseStudiesRecruitingShare
Phase 29690%
Phase 41110%

Most active sponsors

Lead sponsors with the most studies (Marginal Zone Lymphoma(MZL))
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine21
The First Affiliated Hospital with Nanjing Medical University22
Beijing Tongren Hospital11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Fei Li11
Ruijin Hospital11
Sun Yat-sen University10
The First Affiliated Hospital of Soochow University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.